title: Nosocomial pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate.
abstract: BACKGROUND
  Recent studies have questioned the use of histamine (H2) receptor antagonist in stress ulcer prophylaxis because of an increased incidence of nosocomial pneumonia and subsequent death.
  
  
  METHODS
  This prospective randomized study compared prophylaxis with cimetidine vs sucralfate.
  
  
  METHODS
  Medical/surgical intensive care unit in Springfield, Mass.
  
  
  METHODS
  One hundred fourteen patients were enrolled.
  
  
  METHODS
  Cimetidine, administered as a primed continuous infusion using a 300-mg bolus followed by 37.5 mg/h, was compared with sucralfate, administered via nasogastric tube, at a dosage of 1 g every 6 hours suspended in 20 mL of sterile water.
  
  
  METHODS
  End points of the study included nosocomial pneumonia, gastrointestinal hemorrhage, and death.
  
  
  RESULTS
  Fifty-six patients were randomized to receive cimetidine and their rate of pneumonia was 12.5%; upper gastrointestinal hemorrhage, 3.6%; and mortality, 33.9%. Fifty-eight patients were given sucralfate, and their rate of pneumonia was 13.8%; upper gastrointestinal hemorrhage, 3.4%; and mortality, 37.9%. There were no significant differences between these study end points. In patients who had pneumonia, 80% of isolates were aerobic gram-negative bacilli.
  
  
  CONCLUSIONS
  These observations suggest that the rate of nosocomial pneumonia is not increased in patients in the intensive care unit who receive prophylaxis with cimetidine to prevent stress ulcer bleeding.
authors.affiliation: Department of Medicine and Surgery, Baystate Medical Center, Springfield, Mass.
authors.forename: P
authors.initials: P
authors.lastname: Ryan
authors.forename: J
authors.initials: J
authors.lastname: Dawson
authors.forename: D
authors.initials: D
authors.lastname: Teres
authors.forename: G
authors.initials: G
authors.lastname: Celoria
authors.forename: F
authors.initials: F
authors.lastname: Navab
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002927:Cimetidine / Q000008:administration & dosage / Q000009:adverse effects*; D003428:Cross Infection / Q000139:chemically induced* / Q000453:epidemiology* / Q000382:microbiology / Q000401:mortality; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000453:epidemiology / Q000209:etiology; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D011014:Pneumonia / Q000139:chemically induced* / Q000453:epidemiology* / Q000382:microbiology / Q000401:mortality; D011446:Prospective Studies; D012307:Risk Factors; D013312:Stress, Physiological / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D013392:Sucralfate / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D013392:Sucralfate; D002927:Cimetidine